A decision frame for patients weighing the options
Quick answer
Standard drugs such as ACEi/ARB and SGLT2 inhibitors are backed by large randomised trials showing real slowing of kidney decline, while stem cell infusion remains investigational with limited data and much higher cost. The rational path is to maximise standard therapy first, then consider cell therapy only as a supervised adjunct.
The decisive difference is evidence level. Standard drugs were tested in thousands to tens of thousands of patients against placebo with multi-year follow-up; kidney cell therapy studies are mostly small and safety-focused.
The second difference is access and continuity: standard drugs are available in Thailand, often reimbursable and taken daily, whereas cell programmes require travel, out-of-pocket payment and spaced sessions.
That said, standard drugs do not halt progression in everyone; some patients keep declining despite full therapy. That is why cell therapy research continues, and why patients should ask whether any trial is recruiting.
In principle cell therapy is an adjunct, not a replacement; a nephrologist must confirm individual safety.
A small initial shift can reflect intra-renal pressure changes that clinicians anticipate and monitor.
Review the cause, adherence, blood pressure and sodium, and consider enrolling in a study.
Not necessarily; price reflects manufacturing and service costs, not proof of efficacy.
Track eGFR and UACR trends over several time points against your own prior slope.
5 points • reviewed 2026-09-02
Reviewed and last updated: 2026-09-02
5 sources • every claim is traceable
https://www.ehlbio.co.kr
https://www.mfds.go.kr/eng/index.do
https://www.mohw.go.kr/eng/
https://pubmed.ncbi.nlm.nih.gov/
https://www.medicalkorea.or.kr/
Last updated: 2026-09-02 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categories